• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Localized delivery of chemo improves prognosis of recurrent glioblastoma

March 6, 2017 By Sarah Faulkner

Study: Localized delivery of chemo improves prognosis of recurrent glioblastomaResearchers from Amrita University in India demonstrated that localized and sustained delivery of a chemotherapeutic agent in brain tumors can improve the prognosis of recurrent glioblastoma. The team’s work was published in Scientific Reports.

Although new drugs have been developed for glioblastoma multiforme, the overall survival rate for patients remains dismally low at 12 months, with a 3-year long term survival rate of 3% to 5%. Newly developed drugs face several delivery-related challenges, including poor drug accumulation in the brain tumor site and the inability to sustain adequate drug concentration in the tumor.

The team hypothesized that localizing and sustaining delivery of chemo drugs directly into the tumor for long periods of time without leakage into the peripheral blood could be ideal for treating patients with glioblastoma.

Arbor Pharmaceuticals’ Gliadel is the only FDA-approved intracranial drug delivery system and has been available in the clinic for the last 20 years. The microparticle implant delivers carmustine, an oncolytic agent, for 7 days and provides an improved survival advantage of more than 2 months. However, the Amrita University team noted that tumor recurrence has been reported in many of the patients treated with Gliadel, suggesting that the 7-day release may not be enough to stop tumor growth.

Many polymer-based systems loaded with cancer drugs such as doxorubicin and paclitaxel do not deliver drugs intracranially for more than 2 to 3 weeks, the researchers wrote.

The team developed a library of drug-loaded polyester nanofibers and electrospun them together, forming a 3D composite nanofiber implant capable of releasing the anti-glioma drug temozolomide continuously for 1 month into the brain tumor. The researchers optimized the implant’s nanofibers using in vivo brain drug release experiments, designing a composite implant formed from multiple nanofibers.

Then, the team co-electrospun suitable polymer-drug blends into a common target and formed a 3D wafer made of various nanofibers capable of releasing the drug for periods ranging from 1 day to 1 month. The authors tested 2 implants – TMZ-FR for 1 week release and TMZ-SR for 1 month release.

Animals implanted with the 1-month device had a long-term survival rate of 85.7%, compared to 54.6% in animals that received the 7-day implant. The team also noted that their wafers showed constant drug release with negligible leakage into the peripheral blood.

They concluded that this work underscores the importance of highly controlled, localized drug delivery to improve the prognosis for recurrent glioblastoma.

Filed Under: Drug-Device Combinations, Featured, Implants, Neurological, Preclinical Trials, Research & Development Tagged With: Amrita University, Arbor Pharmaceuticals

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS